Description of Procedure or Service

Single nucleotide polymorphisms (SNPs) refer to single-base pair changes that achieve a population frequency of at least 1 percent. They represent the most abundant form of genetic variation and are responsible for much of the heritable phenotypic variation observed in human populations but are not clearly deleterious.

Related Policies:

AHS-M2020 Molecular Diagnostics for Breast Cancer Prognosis

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

Use of common genetic variants to predict risk of non-familial breast cancer is considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. 

When Use of Common Genetic Variants to Predict Risk is covered

Not applicable.

When Use of Common Genetic Variants to Predict Risk is not covered

For all situations, testing for one or more single nucleotide polymorphisms (SNPs) to estimate an individual’s risk for developing breast cancer (e.g., OncoArray, TruSight^®, and BREVAGenplus^™ breast cancer tests; tests offered directly to consumers) is investigational for all indications.

Policy Guidelines

In the United States, breast cancer is the second most diagnosed cancer following skin cancer, and the second most common cause of cancer death in women, following lung cancer. Approximately one in eight women will develop breast cancer in their lifetime. 

Breast cancer risk is strongly associated with both genetic and environmental factors. Familial aggregation and twin studies have shown the substantial contribution of inherited susceptibility to breast cancer. Many genetic loci are known to contribute to this risk, including genes with high-penetrance mutations (notably BRCA1 and BRCA2), moderate-risk alleles in genes such as ATM, CHEK2 and PALB2, and common lower penetrance alleles, of which almost 80 have been identified so far, principally through genome-wide association studies. GWAS continues to uncover additional loci with 65 loci identified by Michailidou, et al (2017). Coupled with established risk factors, these loci are likely to increase the utility and accuracy of clinical risk prediction.

For sporadic (non-familial) breast cancer, the Breast Cancer Risk Assessment Tool (BCRAT), most often referred to as the Gail model  is commonly used to produce individual risk estimates in women. The model incorporates individual risk factors including age, family history (breast cancer among first-degree relatives), personal reproductive history (age at menarche and at first live birth), and personal medical history (number of previous breast biopsies and presence of biopsy-confirmed atypical hyperplasia) to identify women who have an increased 5-year risk and lifetime risk of invasive breast cancer and may benefit from risk reduction with selective estrogen receptor (ER) modulators. While this model has implications for primary prevention of invasive breast cancer, both the discriminatory accuracy of the Gail model and its calibration in certain populations have been challenged. In 2018, Wang et al. (2018) systematically reviewed and analyzed the performance of different versions of the Gail model. They did find that the original Gail model 1 and the Caucasian-American Gail model was well calibrated in American and European women. However, in contrast, the Caucasian-American and Asian-American Gail models likely overestimate the risk in Asian females, providing a risk roughly double that of their actual risk. 

It has been noted that the “effect of single SNPs in complex disease to date has been small (i.e., odds ratios in the 1.1-1.6 range).” However, previous studies have analyzed the potential impact of adding genetic information from a panel of (SNPs) associated with breast cancer risk to the Gail model. SNPs are specific locations in the genome where a nucleotide differs between individuals. A study that compared classification of risk using the Gail model or the Gail model plus 10 common genetic susceptibility variants, other than those associated with BRCA1 or BRCA2, found that inclusion of the genetic factors only modestly improved performance of the risk model for breast cancer. Another study evaluated the inclusion of a SNP risk score, based on seven SNPs associated with risk for breast cancer, in a risk model combined with the Gail model. These showed that real gains, albeit modest, could be achieved in reclassification of risk. Other studies have found modest potential clinical gains from combining SNP information with clinical risk factors. However, these studies have either been theoretical in nature  or they combined model building with evaluation, which may complicate evaluating the results in clinical context. Improvement in risk assessment from incorporating genetic information might be larger in subsets of women at intermediate risk based on clinical risk factors. Moreover, it should be cautioned that though “Success in creating risk scores with a handful of SNPs has led some to try creating risk scores with tens or hundreds of thousands of SNPs, hoping to increase predictive power," the predictive power of these attempts tend to level off very rapidly. In one instance, increasing the number of SNPs examined from tens to millions only explained two to four percent of the variance in disease risk.

Proprietary Testing

Proprietary tests exist for the assessment of SNPs in breast cancer risk. TruSight evaluates 94 genes and 284 SNPs related to common and rare cancers, including breast cancer. BREVAGenplus, now GeneType for Breast Cancer, measures 66 genes and 77 loci for Caucasian women, 74 for African American women, and 71 for Hispanic women; Inifinium OncoArray-500k covers over 500,000 SNPs associated with many types of cancer, as well as other features such as ancestry and pharmacogenetics. 

Clinical Utility and Validity

A 76-locus polygenic risk score (PRS) was incorporated into the Breast Cancer Surveillance Consortium (BCSC) risk-prediction model  while accounting for its attributable risk and compared five-year absolute risk predictions between models within three studies (1643 case patients, 2397 control patients). PRS was found to be an independent risk factors across all three studies and improved discriminatory accuracy from area under the curve (AUC) AUC = 0.66 to AUC = 0.69. The study concluded that the set of 76 SNPs improves the identification of women at the highest risk. Along with the increase seen in AUC, the net-reclassification of 11% of case patients (95% CI = 7% to 15%) to a risk level where women are more likely to benefit from chemoprevention suggests that SNPs could be useful clinically. However, independent cohort data are needed to test calibration in the general population. 

Michailidou, et al. (2017) performed a GWAS on breast cancer, encompassing “122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry.” Overall, they identified 65 new loci associated at a genome-wide level with overall breast cancer risk (defined as P < 5 × 10-8). The authors concluded that “these results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.” 

Cuzick et al (2017) developed a SNP risk score (SNP88) using the Illumina OncoArray, which includes most known breast-cancer risk SNPs (previously validated and directly available or with close surrogates on the OncoArray) in women receiving preventative treatment. They found that “SNP88 was predictive of breast cancer risk overall (interquartile range odds ratio [IQ-OR], 1.37), but mainly for estrogen receptor-positive disease (IQ-OR, 1.44) versus estrogen receptor-negative disease. However, the observed risk of SNP88 was only 46% of expected. No significant interaction was observed with treatment arm. SNP88 was independent of TC (Spearman rank-order correlation, 0.012) and when combined multiplicatively, a “substantial” improvement was seen (IQ-OR, 1.64).” 

Mavaddat et al (2015) evaluated the value of using 77 breast cancer related SNPs for risk stratification. A total of 33,673 breast cancer cases and 33,381 controls were analyzed. All possible pair-wise multiplicative interactions were examined and a 77-SNP (PRS) was created for (ER) status, as well as breast cancer overall. The authors found that women in the highest 1% of the PRS had a “three-fold increased risk” compared to women in the middle quintile (odds ratio = 3.36). Lifetime risk of breast cancer for women without a family history that had a PRS in the lowest and highest quintiles were 5.2% and 16.6%, respectively. 

Rudolph et al. (2018) investigated the integration of PRS into risk prediction models, combining PRS and environmental risk factors. The authors performed a retrospective review of 20 studies and evaluated joint associations of the 77-SNP PRS with several environmental factors such as body mass index (BMI) and alcohol use. They found that “the strongest evidence for a non-multiplicative joint association with the 77-SNP PRS was for alcohol consumption, adult height, and current use of combined menopausal hormone therapy in ER-positive disease. Risk associations for these factors by percentiles of PRS did not follow a clear dose-response. In addition, global and tail-based goodness of fit tests showed little evidence for departures from a multiplicative risk model, with alcohol consumption showing the strongest evidence for ER-positive disease (P = 0.013 for global and 0.18 for tail-based tests)” (Rudolph et al., 2018). They concluded that “the combined effects of the 77-SNP PRS and environmental risk factors for breast cancer are generally well described by a multiplicative model.” 

Schuetz et al. (2019) researched genetic variants and the relationship between inflammation, apoptosis, and autophagy in breast cancer risk. In total, 206 SNPs were tested in 54 genes related to inflammation, apoptosis, and autophagy in a population-based breast cancer study; this study included women of both European descent (658 with breast cancer and 795 controls) and East Asian descent (262 with breast cancer and 127 controls). The researchers report that “although no SNP was associated with breast cancer risk among women of European descent, we found evidence for an association among East Asians for rs1800925 (IL-13) and breast cancer risk (OR = 2.08; 95% CI: 1.32-3.28; p = 0.000779), which remained statistically significant after multiple testing correction” (Schuetz et al., 2019). The researchers also report that “This association was replicated in a meta-analysis of 4305 cases and 4194 controls in the Shanghai Breast Cancer Genetics Study.” 

Kapoor et al. (2020) assessed potential interactions between 205 breast cancer susceptibility loci and 13 established breast cancer risk factors. A total of 28,176 cases and 32,209 controls were analyzed with the iCOGS array (a custom SNP genotyping array), and 44,109 cases and 48,145 controls were genotyped using the OncoArray. An interaction with less than or equal to 1% prior probability was found with three different SNP risk factor pairs. “SNP rs4442975 was associated with a greater reduction of risk of ER-positive breast cancer… in current users of estrogen-progesterone therapy compared with non-users. This finding was supported by replication using OncoArray data of the previously reported interaction between rs13387042 (r2 = 0.93 with rs4442975) and current estrogen-progesterone therapy for overall disease (Pint = 0.004). The two other interactions suggested stronger associations between SNP rs6596100 and ER-negative breast cancer with increasing parity and younger age at first birth.” 

Shu et al. (2020) performed a meta- analysis of data from GWAS conducted in Asians (24,206 cases, 24,775 controls) and European descendants (122,977 cases, 105,974). The focus of their study was identifying additional genetic susceptibility loci for breast cancer, as currently known risk variants only explain a small portion of breast cancer heritability, particularly in Asian women. In this study, they identified 31 potential novel risk loci, with the lead variant showing an associate with breast cancer risk at p<5x10-8. Of note, “the associations for 10 of these loci were replicated in an independent sample of 16,787 cases and 16,680 controls of Asian women (P < 0.05). In addition, we replicated the associations for 78 of the 166 known risk variants at P < 0.05 in Asians. These findings improve our understanding of breast cancer genetics and etiology and extend previous findings from studies of European descendants to Asian women.” 

Zhang et al. (2020) note that “breast cancer susceptibility variants frequently show heterogeneity in associations by tumor subtype... defined by combinations of ER, [progesterone receptor] PR, [human epidermal growth factor 2] HER2 and grade: (1) luminal A-like, (2) luminal B/HER2-negative-like, (3) luminal B-like, (4) HER2-enriched-like and (5) triple-negative or basal-like”  To identify novel breast cancer loci, they performed a GWAS (133,384 breast cancer cases, 113,789 controls, plus 18,908 BRCA1 mutation carriers, 9,414 of them with breast cancer) on patients with European ancestry. They identified 32 novel susceptibility loci (p<5x10-8), 15 of which showed associations with at least one tumor feature. Five loci showed opposite associations (p<0.05) between luminal- and non-luminal subtypes. They also found that “the genetic correlations between five intrinsic-like subtypes ranged from 0.35 to 0.80. The proportion of genome-wide chip heritability explained by all known susceptibility loci was 37.6% for triple-negative and 54.2% for luminal A-like disease. The odds ratios of polygenic risk scores (PRSs), which included 330 variants, for the highest 1% quantiles compared to middle quantiles were 5.63 and 3.02 for luminal A-like and triple-negative disease, respectively. These findings provide an improved understanding of genetic predisposition to breast cancer subtypes and will inform the development of subtype-specific polygenic risk scores.” 

Adedokun et al. (2021) used a cross-ancestry GWAS approach to describe breast cancer risk loci. They identified breast cancer variants in individuals from African ancestry GWAS (9,421 cases, 10,193 controls) and meta-analyzed them with European ancestry GWAS data (122,977 cases, 105,974 controls). The identified “four loci for overall breast cancer risk [1p13.3, 5q31.1, 15q24 (two independent signals), and 15q26.3] and two loci for estrogen receptor-negative disease (1q41 and 7q11.23) at genome-wide significance.” This study suggests that replication across multiple ancestry populations will “help improve the understanding of breast cancer genetics and identify causal variants.” 

Chen et al. (2022) conducted a “genome-wide association study, as well as a transcriptome-wide association study (TWAS), of age- and BMI- adjusted DA, NDA, and PMD in up to 27,900 European-ancestry women from the MODE/BCAC consortia.” In their results they identified 28 genome-wide significant loci for MD phenotypes and found that 45% of all known breast cancer SNPs were associated with at least one MD phenotype. Also, “TWAS identified two novel genes (SHOX2 and CRISPLD2) whose genetically predicted expression was significantly associated with MD phenotypes.” In conclusion, their findings provided insight into the genetic background of MD phenotypes, and further demonstrated their shared genetic basis with breast cancer. 

Jia et al. (2023) studied the association between SNPs and overall breast cancer risk in the Chinese female population, stating that “frequencies vary across ethnic group.” Thirty-four SNPs were included in the study, all of which had been previously identified by GWAS. The authors conducted an association analysis, including 1848 patients with breast cancer and 709 healthy controls. The authors identified a a significant association between SNP rs12493607 and breast cancer risk, as well as invasive carcinoma, (ER)-positive, progesterone receptor (PR)-positive, HER2-negative, and young (aged younger than 45) breast cancer. The authors also identified “less conservatively” significant association with rs4784227 and rs2046210 and breast cancer risk. Overall, the authors concluded that the results “shed light on the relationship between SNPs and breast cancer susceptibility within a vast Chinese cohort, supporting the development of polygenetic risk scores for the Chinese population.”

State and Federal Regulations, as applicable

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Guidelines and Recommendations

American Society of Clinical Oncology (ASCO)

An update from the American Society of Clinical recommendation for genetic and genomic testing for cancer susceptibility. These guidelines state, “ASCO recognizes that concurrent multigene testing (i.e panel testing) may be efficient in circumstances that require evaluation of multiple high-penetrance genes of established clinical utility as possible explanations for a patient’s personal or family history of cancer. Depending on the specific genes included on the panel employed, panel testing may also identify mutations in genes associated with moderate or low cancer risks and mutations in high-penetrance genes that would not have been evaluated on the basis of the presenting personal or family history. Multigene panel testing will also identify variants of uncertain significance (VUSs) in a substantial proportion of patient cases, as a result of the multiplicity of genes tested. ASCO affirms that it is sufficient for cancer risk assessment to evaluate genes of established clinical utility that are suggested by the patient’s personal and/or family history.

National Comprehensive Cancer Network (NCCN)

Prior to 2020, the NCCN guidelines focused largely on testing BRCA1/2. However, the NCCN has since updated their guidelines based on strong evidence that genes beyond BRCA1/2, TP53, and PTEN confer markedly increased risk of breast and/or ovarian cancers.”  These NCCN guidelines acknowledge that “Multi-gene testing can detect P/LP variants not found in single-gene testing,” but “Since more than one gene can explain an inherited cancer syndrome. Phenotype-directed testing based on personal and family history through a multi-gene panel test is often more efficient and/or cost-effective. Furthermore, Multi-gene testing may also be considered for those who tested negative for one particular syndrome, but who’s personal and family history is suggestive of an inherited susceptibility.” The NCCN also stated that “Multi-gene tests also increase the likelihood of detecting a VUS.” The NCCN recommends that “for individuals potentially meeting established criteria for one or more of the hereditary cancer syndromes, genetic testing should be considered along with appropriate pre- and post-test counseling.” 

The NCCN Panel recommends that “Multi-gene testing may be considered for individuals who meet testing criteria and who previously underwent single-gene and/or absent deletion duplication analysis but tested negative. Both first- and second-degree relatives of individuals who meet these testing criteria are also eligible for testing, except for second-degree relatives of individuals with pancreatic cancer or prostate cancer, for whom prior probability of a high-penetrance cancer susceptibility gene is low in the absence of additional family history of cancer; only first-degree relatives of these affected individuals should be offered testing, unless indicated based on additional family history. It should be noted that “Carriers of a P/LP variant should be encouraged to participate in clinical trials or genetic registries. Carriers should be encouraged to recontact their genetics providers every few years for updates, as laboratories may issue amended reports as the knowledge base surrounding hereditary cancer risk expands.” 

However, “a major dilemma regarding multi-gene testing is that there are limited data and a lack of clear guidelines regarding degree of cancer risk associated with some of the genes assessed, and how to communicate and manage risk for carriers of these genes.” This issue is exacerbated by the “low incidence rates of hereditary disease, leading to a difficulty in conducting adequately powered studies” and the fact that “Multi-gene tests include moderate-penetrance genes, and they often also include low-penetrance genes for which there are little available data regarding degree of cancer risk and guidelines for risk management.” 

The NCCN states, “Reports regarding germline findings that may impact medical management should come from laboratories that are certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), with some U.S. states (eg., New York) having additional reporting requirements. The testing typically used by companies providing ancestry information directly to consumers is microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. These companies do not provide comprehensive genetic analysis that includes gross deletion or duplication analysis. Third-party services are available to assist patients with interpreting their raw data, but these services are not government-regulated. In addition to the errors inherent in working with raw data from DTC [direct-to-consumer] labs, other limitations of these services include inadequate informed consent process, uncertain clinical validity and utility, and lack of medical oversight.” As such, “Given the limitations of the information obtained from DTC services, confirmatory germline testing by a certified laboratory is clinically indicated and changes to medical management based solely on DTC testing results are not recommended.” 

Finally, “Confirmatory germline testing through an appropriately certified laboratory is clinically indicated when a potential P/LP variant is identified through various data sources” as listed below:

• Commercial entities providing ancestry (and sometimes health) information typically do so through microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. Third-party software applications can be used by consumers to obtain an interpretation of the raw data provided by these companies. Raw data and third-party software are not able to provide information that is appropriate for medical management, as these services are not subject to quality-control processes and recent research suggests that the error rate (40%) is substantial. In addition, the current tests only provide limited founder pathogenic variants results without the benefit of family history. More comprehensive genetic counseling and testing for pathogenic variants in other inherited cancer risk genes may be appropriate at the time of confirmation testing.”
• “Commercial laboratories utilizing consumer-initiated or direct-to-consumer (DTC) marketing of DNA sequence-based cancer predisposition tests vary substantially in providing information necessary to make informed decisions regarding results and may vary in accuracy in their variant interpretation” 
• “Research: Patients may have participated in research studies that included germline genomic analysis…In such cases, it is clinically indicated to review the patient's findings with a genetics professional and/or the reporting laboratory to establish whether the original report was generated by an appropriately certified laboratory, or whether confirmatory testing is clinically indicated.”

The United States Preventive Services Task Force (USPSTF)

The USPSTF published recommendations related to genetic testing for breast cancer. In particular, “The USPSTF found adequate evidence that the benefits of risk assessment, genetic counseling, and genetic testing are moderate in women whose family history is associated with an increased risk for harmful mutations in the BRCA1/2 genes,” whereas for women without such family history, it stated that the benefits are small to none. They concluded with moderate certainty that the net benefit of these procedures outweighs the harms in women both with and without a familial risk of potentially harmful mutations. The USPSTF does not address the use of SNPs as a screening method for cancer.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 81599

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included. 

Scientific Background and Reference Sources

Attia J. Genetic association and GWAS studies: Principles and applications. Updated March 20, 2024. https://www.uptodate.com/contents/genetic-association-and-gwas-studies-principles-and-applications 

MedlinePlus. What are single nucleotide polymorphisms (SNPs)? National Library of Medicine. Updated March 22, 2022. https://medlineplus.gov/genetics/understanding/genomicresearch/snp/ 

ACS. Key Statistics for Breast Cancer. Updated May 5, 2025. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html 

Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England journal of medicine. Jul 13, 2000;343(2):78-85. doi:10.1056/nejm200007133430201

Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nature genetics. Dec 2000;26(4):411-4. doi:10.1038/82533 

Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature genetics. Apr 2013;45(4):353-361e2. doi:10.1038/ng.2563 

Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature genetics. Oct 2010;42(10):885-92. doi:10.1038/ng.669 

Hussaini M, Fletcher O, Michailidou K, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature genetics. Jan 22, 2012;44(3):312-8. doi:10.1038/ng.1049 

French JD, Ghoussaini M, Edwards SL, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. American journal of human genetics. Apr 04, 2013;92(4):489-503. doi:10.1016/j.ajhg.2013.01.002 

Fletcher O, Johnson N, Orr N, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. Journal of the National Cancer Institute. Mar 02, 2011;103(5):425-35. doi:10.1093/jnci/djq563 

Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature genetics. Mar 2009;41(3):324-8. doi:10.1038/ng.318 

Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nature genetics. Jun 2010;42(6):504-7. doi:10.1038/ng.586 

Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007-05-27 2007;447(7148):1087-1093. doi:10.1038/nature05887 

Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nature genetics. Jun 2008;40(6):703-6. doi:10.1038/ng.131 

Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature genetics. Apr 2013;45(4):371-84, 384e1-2. doi:10.1038/ng.2566 

Haiman CA, Chen GK, Vachon CM, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature genetics. Oct 30, 2011;43(12):1210-4. doi:10.1038/ng.985 

Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature genetics. May 2009;41(5):585-90. doi:10.1038/ng.354 

Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nature genetics. Jul 2007;39(7):865-9. doi:10.1038/ng2064 

Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nature genetics. Mar 2007;39(3):352-8. doi:10.1038/ng1981 

Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature genetics. Apr 2013;45(4):392-8, 398e1-2. doi:10.1038/ng.2561 

Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature genetics. May 2009;41(5):579-84. doi:10.1038/ng.353 

Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. Journal of the National Cancer Institute. May 2015;107(5)doi:10.1093/jnci/dju397 

Michailidou K, Lindstrom S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. Nov 2, 2017;551(7678):92-94. doi:10.1038/nature24284 

Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute. Dec 20, 1989;81(24):1879-86. doi:10.1093/jnci/81.24.1879 

Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 01, 2009;27(19):3235-58. doi:10.1200/jco.2008.20.5179 

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. Jul 02, 2002;137(1):59-69. doi:10.7326/0003-4819-137-1-200207020-00017 

Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information. Journal of the National Cancer Institute. Nov 03, 2010;102(21):1618-27. doi:10.1093/jnci/djq388 

Wang X, Huang Y, Li L, Dai H, Song F, Chen K. Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis. Breast Cancer Res. Mar 13, 2018;20(1):18. doi:10.1186/s13058-018-0947-5 

Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. Journal of the National Cancer Institute. Jul 16, 2008;100(14):1037-41. doi:10.1093/jnci/djn180 

Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. Journal of the National Cancer Institute. Jul 01, 2009;101(13):959-63. doi:10.1093/jnci/djp130 

Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. The New England journal of medicine. Mar 18, 2010;362(11):986-93. doi:10.1056/NEJMoa0907727 

Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. The New England journal of medicine. Jun 26, 2008;358(26):2796-803. doi:10.1056/NEJMsa0708739 

Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature genetics. Sep 2018;50(9):1219-1224. doi:10.1038/s41588-018-0183-z 

Illumina. TruSight Cancer. https://www.illumina.com/products/by-type/clinical-research-products/trusight-cancer.html 

GeneType. Product Specification: GeneType for Breast Cancer. 2019;2021(Jul 28, 2021). https://e13609b8-ed51-46c1-8570-6819a0110aba.filesusr.com/ugd/70aa06_079e41335b874beebc288a6fe4582276.pdf 

GeneType. Brest Cancer Test https://genetype.com/for-medical-practitioners/breast-cancer-test-practitioners-au/ 

Illumina. Infinium OncoArray-500K BeadChip. https://www.illumina.com/products/by-type/microarray-kits/infinium-oncoarray-500k.html 

Vachon CM, Affiliations of authors: Department of Health Sciences Research DoE, Mayo Clinic (CMV, VSP, CGS, MRJ, JEO, ADN, FJC), Department of Gynecology and Obstetrics UHEF-A-UE-N, Comprehensive Cancer Center Erlangen-EMN , Erlangen , Germany (LH, KH, CCH, SMJ, MWB, PAF), et al. The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. JNCI: Journal of the National Cancer Institute. 2017;107(5)doi:10.1093/jnci/dju397 

Cuzick J, Brentnall AR, Segal C, et al. Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Mar 2017;35(7):743-750. doi:10.1200/jco.2016.69.8944 

Mavaddat N, Pharoah PDP, Michailidou K, et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute. May 2015;107(5)doi:10.1093/jnci/djv036 

Rudolph A, Song M, Brook MN, et al. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International journal of epidemiology. Apr 1, 2018;47(2):526-536. doi:10.1093/ije/dyx242 

Schuetz JM, Grundy A, Lee DG, et al. Genetic variants in genes related to inflammation, apoptosis and autophagy in breast cancer risk. PLoS One. 2019;14(1):e0209010. doi:10.1371/journal.pone.0209010 

Kapoor PM, Lindström S, Behrens S, et al. Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. International journal of epidemiology. Feb 1, 2020;49(1):216-232. doi:10.1093/ije/dyz193 

Shu X, Long J, Cai Q, et al. Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nat Commun. Mar 5, 2020;11(1):1217. doi:10.1038/s41467-020-15046-w 

Zhang H, Ahearn TU, Lecarpentier J, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature genetics. Jun 2020;52(6):572-581. doi:10.1038/s41588-020-0609-2 

Adedokun B, Du Z, Gao G, et al. Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nat Commun. Jul 7, 2021;12(1):4198. doi:10.1038/s41467-021-24327-x 

Chen H, Fan S, Stone J, et al. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Res. Apr 12, 2022;24(1):27. doi:10.1186/s13058-022-01524-0 

Jia Z, Huang Y, Liu J, et al. Single nucleotide polymorphisms associated with female breast cancer susceptibility in Chinese population. Gene. Oct 30, 2023;884:147676. doi:10.1016/j.gene.2023.147676 

Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Nov 01, 2015;33(31):3660-7. doi:10.1200/jco.2015.63.0996 

NCCN. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2026 — July 10, 2025. Updated July 10, 2025. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf 

USPSTF. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. Updated August 20, 2019. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing 

Medical Director review 11/2019 

Specialty Matched Consultant Advisory Panel 3/2020

Medical Director review 3/2020

Medical Director review 10/2020

Specialty Matched Consultant Advisory Panel 3/2021

Medical Director review 3/2021

Medical Director review 11/2022

Medical Director review 10/2023

Medical Director 7/2024

Medical Director 11/2025

Policy Implementation/Update Information

1/1/2019 New policy developed. Testing for one or more single nucleotide polymorphisms (SNPs) is investigational for all indications, including but not limited to use as a method of estimating individual patient risk for developing breast cancer. These include, but are not limited, to the OncoVue^®, OncoArray, TruSight^®, deCODE BreastCancer^™ and BREVAGenplus,^™ breast cancer tests and tests offered directly to consumers. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (lpr)

10/29/19 No change to policy statements. (hb)

12/31/19 Reviewed by Avalon 3rd Quarter 2019 CAB. Under “When Covered” section: removed OncoVue and deCODE BreastCancer tests since they are no longer commercially available. Added CPT codes 81307, 81308 to the Billing/Coding section for effective date 1/1/2020. Medical Director review 11/2019. (lpr)

3/31/20 Specialty Matched Consultant Advisory Panel review 3/18/2020. No change to policy statement. (lpr) 

11/10/20 Reviewed by Avalon 3rd Quarter 2020 CAB. Literature review only. Updated references and added Related Policies section. Medical Director review 10/2020. (lpr)

4/6/21 Specialty Matched Consultant Advisory Panel review 3/17/2021. No change to policy statement. (lpr)

11/16/21 Reviewed by Avalon 3rd Quarter 2021 CAB. Updated policy guidelines and references. Medical Director review 10/2021. (lpr)

12/13/22 Reviewed by Avalon 3rd Quarter 2022 CAB. Medical Director review 11/2022. Updated policy guidelines and references. Deleted CPT codes 81307, 81308 from Billing/Coding section. No change to policy statement. (lpr)

12/5/23 Reviewed by Avalon 3rd Quarter 2023 CAB. Medical Director review 10/2023. Updated description, policy guidelines and references. (lpr)

9/4/24 Reviewed by Avalon 2nd Quarter 2024 CAB. Medical Director review 7/2024. Updated related policies, policy guidelines and references. (lpr)

2/11/26 Reviewed by Avalon 4^th Quarter 2025 CAB. Medical Director review 11/2025. Updated policy guidelines, guidelines and recommendations, and references. (lpr)